114 related articles for article (PubMed ID: 12431241)
21. Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Lappalainen K; Teerenhovi L; Jalkanen S
Blood; 1997 Nov; 90(10):4039-45. PubMed ID: 9354673
[TBL] [Abstract][Full Text] [Related]
22. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
23. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
24. Predicting the outcome of Sjogren's syndrome-associated non-hodgkin's lymphoma patients.
Papageorgiou A; Ziogas DC; Mavragani CP; Zintzaras E; Tzioufas AG; Moutsopoulos HM; Voulgarelis M
PLoS One; 2015; 10(2):e0116189. PubMed ID: 25723713
[TBL] [Abstract][Full Text] [Related]
25. Non-Hodgkin's lymphomas: immunologic prognostic studies.
Hadzi-Pecova L; Petrusevska G; Stojanovic A
Prilozi; 2007 Jul; 28(1):39-55. PubMed ID: 17921917
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma.
Ozgüroglu M; Turna H; Demir G; Döventas A; Demirelli F; Mandel NM; Büyükünal E; Serdengeçti S; Berkarda B
Am J Clin Oncol; 1999 Dec; 22(6):615-8. PubMed ID: 10597748
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
[TBL] [Abstract][Full Text] [Related]
28. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Iijima K
Leuk Res; 2002 Mar; 26(3):241-8. PubMed ID: 11792412
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin's lymphoma.
Niitsu N; Okamato M; Nakamine H; Yoshino T; Tamaru J; Nakamura S; Higashihara M; Hirano M
Eur J Haematol; 2002 Feb; 68(2):91-100. PubMed ID: 12038454
[TBL] [Abstract][Full Text] [Related]
30. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma.
Sasaki K; Niitsu N
Eur J Haematol; 2000 Sep; 65(3):195-202. PubMed ID: 11007056
[TBL] [Abstract][Full Text] [Related]
31. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma.
Hsiao LT; Lin JT; Yu IT; Chiou TJ; Liu JH; Yen CC; Wang WS; Chen PM
Eur J Haematol; 2003 May; 70(5):282-9. PubMed ID: 12694163
[TBL] [Abstract][Full Text] [Related]
32. [Prognostic significance of the histological classification and staging for patients with a malignant non-Hodgkin lymphoma].
Raemaekers JM; Snoeijen JJ; Bogman MJ; Rutten E; Strijk SP; Manni JJ
Ned Tijdschr Geneeskd; 1993 Apr; 137(16):815-20. PubMed ID: 8487885
[TBL] [Abstract][Full Text] [Related]
33. Application of the international prognostic index in a study of Chinese patients with non-Hodgkin's lymphoma and a high incidence of primary extranodal lymphoma.
Mok TS; Steinberg J; Chan AT; Yeo WM; Hui P; Leung TW; Johnson P
Cancer; 1998 Jun; 82(12):2439-48. PubMed ID: 9635538
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.
Cowan RA; Jones M; Harris M; Steward WP; Radford JA; Wagstaff J; Deakin DP; Crowther D
Br J Cancer; 1989 Feb; 59(2):276-82. PubMed ID: 2930692
[TBL] [Abstract][Full Text] [Related]
35. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
36. The Prognostic Role of Tumor Marker CA-125 in B-Cell non-Hodgkin's Lymphoma.
Memar B; Aledavood A; Shahidsales S; Ahadi M; Farzadnia M; Raziee HR; Noori S; Tayebi-Meybodi N; Amouian S; Mohtashami S
Iran J Cancer Prev; 2015; 8(1):42-6. PubMed ID: 25821570
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic factors in patients with primary non-Hodgkin's lymphoma of the tonsil].
Gao Y; Li Y; Yuan Z; Zhao L; Liu X; Gu D; Qian T; Yu Z
Zhonghua Zhong Liu Za Zhi; 2002 Sep; 24(5):483-5. PubMed ID: 12485504
[TBL] [Abstract][Full Text] [Related]
38. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor.
Blay JY; Burdin N; Rousset F; Lenoir G; Biron P; Philip T; Banchereau J; Favrot MC
Blood; 1993 Oct; 82(7):2169-74. PubMed ID: 8400266
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.
Stasi R; Zinzani PL; Galieni P; Lauta VM; Damasio E; Dispensa E; Dammacco F; Papa G; Tura S
Br J Haematol; 1994 Dec; 88(4):770-7. PubMed ID: 7819101
[TBL] [Abstract][Full Text] [Related]
40. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
